Related Experiment Video

Updated: Nov 5, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

851

Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis

Qiu Wei1,2, Hua Lin2, Rong-Guo Wei2

  • 1Department of Respiratory and Critical Care, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530022, People's Republic of China.

Infectious Diseases of Poverty
|May 18, 2021
PubMed
Abstract

Insights

Tocilizumab treatment significantly lowers mortality risk and the need for mechanical ventilation in COVID-19 patients. This finding is particularly pronounced in critical cases, suggesting tocilizumab

Area of Science:

  • Immunomodulatory therapies
  • Critical care medicine
  • Infectious diseases

Background:

  • Coronavirus disease 2019 (COVID-19) has caused millions of deaths globally.
  • Effective treatments for COVID-19 remain a critical unmet need.
  • Tocilizumab is an interleukin-6 receptor inhibitor with immunomodulatory properties.

Purpose of the Study:

  • To evaluate the efficacy of tocilizumab in improving clinical outcomes for COVID-19 patients.
  • To assess the impact of tocilizumab on mortality and mechanical ventilation requirements.
  • To identify patient subgroups that may benefit most from tocilizumab therapy.

Main Methods:

  • A systematic review and meta-analysis of 25 publications.
  • Searched major scientific databases for relevant studies.
  • Analyzed data using Revman 5.3 and R software.

Main Results:

  • Tocilizumab treatment was associated with significantly better clinical outcomes compared to standard care (OR = 0.70, P = 0.007).
  • Reduced mortality was observed in patients under 65 years old (OR = 0.68) and in intensive care unit patients (OR = 0.62).
  • Tocilizumab predicted better overall survival, especially in severe COVID-19 cases (HR = 0.58).

Conclusions:

  • Tocilizumab treatment is linked to a reduced risk of mortality and mechanical ventilation in COVID-19 patients.
  • The drug demonstrates substantial effectiveness in decreasing mortality, particularly in critical cases.
  • This review supports the potential therapeutic role of tocilizumab in managing COVID-19.
Keywords:
COVID-19Cytokine stormIL-6Tocilizumab

More Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.5K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

423

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
514
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.8K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
266